Cited by 369Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 224 of the 230 references it cites were found in a registry or an index.

Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy

Constantinidou, Anastasia, Alifieris, Constantinos, Trafalis, Dimitrios T.·2019·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2018.09.008

Open this paper in CoChat — free account

Abstract

Improved understanding of the immune system and its role in cancer development and progression has led to impressive advances in the field of cancer immunotherapy over the last decade. Whilst the field is rapidly evolving and the list of drugs receiving regulatory approval for the treatment of various cancers is fast growing, the group of PD1- PDL-1 inhibitors is establishing a leading role amongst immunomodulatory agents. PD1- PDL-1 inhibitors act against pathways involved in adaptive immune suppression resulting in immune checkpoint blockade. Within the last four years two PD-1 and three PD-L1 inhibitors have been utilized in clinical practice against a variety of malignancies. Focus was initially placed on targeting cancers considered immunogenic such as melanoma, renal and lung cancers but subsequently the application expanded to include amongst others Hodgkin Lymphoma, urothelial as well as head and neck cancer. This article provides a comprehensive review of the early and late phase trials that led to the regulatory approval of all five PD1- PDL-1 inhibitors in the corresponding cancer types. It presents available data on the combinations of PD1- PDL-1 inhibitors with other therapies (immunotherapy, targeted therapy and chemotherapy), the toxicity profile of the PD1- PDL-1 inhibitors and ongoing trials testing the efficacy of these agents in cancer types beyond those that have been addressed already. Finally, current and future challenges in the application of PD-1 and PD-L1 inhibitors are discussed with emphasis on the role of predictive biomarkers.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2018.09.008

Cites

224 of 224 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Flagged first, then by citations

Show all 230 references

6 of the 230 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Escudier, 2017, Annals of Oncology, 28

Sorted by citations

Items 201–300 of 369

Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer
Lu, M., Zhang, R., Qi, L., Wang, Y., Sun, X., & You, J. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14679 · Cited by 9
Monitoring Immunotherapy With Optical Molecular Imaging
Xu, L., Wang, Y., Ma, Y., Huan, S., & Song, G. (2021) · ChemMedChem · doi:10.1002/cmdc.202100260 · Cited by 9
Theoretical and experimental studies on the interaction of biphenyl ligands with human and murine PD-L1: Up-to-date clues for drug design
Donati, G., D’Amore, V. M., Russomanno, P., Cerofolini, L., Amato, J., Marzano, S., Salobehaj, M., Rizzo, D., Assoni, G., Carotenuto, A., et al. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.06.006 · Cited by 9
Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials
Zhang, Z., Huang, J., Xu, Y., & Luo, H. (2023) · MedComm – Future Medicine · doi:10.1002/mef2.56 · Cited by 8
Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction
Xu, C., Sun, Z., Zhang, X., Zang, Q., Yang, Z., Li, L., Yang, X., He, Y., Ma, Z., & Chen, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107376 · Cited by 8
Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma
Okamura, K., Inoue, H., Tanaka, K., Ikematsu, Y., Furukawa, R., Ota, K., Yoneshima, Y., Iwama, E., & Okamoto, I. (2022) · Cancer Science · doi:10.1111/cas.15645 · Cited by 7
Redox Signaling Modulates Activity of Immune Checkpoint Inhibitors in Cancer Patients
Allegra, A., Murdaca, G., Mirabile, G., & Gangemi, S. (2023) · Biomedicines · doi:10.3390/biomedicines11051325 · Cited by 8
PTPRD/PTPRT mutation correlates to treatment outcomes of immunotherapy and immune landscape in pan-cancers
Wang, G., Ji, X., Wang, H., Tang, X., Xing, X., & Ji, J. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.03.09 · Cited by 8
Multi-omics analysis reveals the unique landscape of DLD in the breast cancer tumor microenvironment and its implications for immune-related prognosis
Xu, L., Yang, L., Zhang, D., Wu, Y., Shan, J., Zhu, H., Lian, Z., He, G., Wang, C., & Wang, Q. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.02.016 · Cited by 8
Dostarlimab: A breakthrough in the field of oncology
Hussain, H. U., Burney, M. H., Rehan, S. T., & Hasan, M. M. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104046 · Cited by 8
Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review
Liu, Q., Lin, H., Han, H.-W., Yang, C., Liu, C., & Zhang, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.803454 · Cited by 8
Nucleic acid‐based small molecules as targeted transcription therapeutics for immunoregulation
Bai, D., Ziadlou, R., Vaijayanthi, T., Karthikeyan, S., Chinnathambi, S., Parthasarathy, A., Cai, L., Brüggen, M., Sugiyama, H., & Pandian, G. N. (2023) · Allergy · doi:10.1111/all.15959 · Cited by 7
Research progress and future perspectives of prodrug strategies for immune checkpoint inhibitors in cancer immunotherapy
Li, T., Gao, S., Dong, D., Chen, Y., & Li, S. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104905 · Cited by 7
PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer
Li, X., Fan, Y., Tang, M., Li, H., Zhang, Y., Mi, J., Wang, Y., Zhao, M., Wang, Z., & Su, F. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s383191 · Cited by 8
Immunotherapy Treatment Against Cervical Cancer
Jiménez-Lima, R., Arango-Bravo, E. A., Galicia-Carmona, T., Lino-Silva, L. S., Trejo-Durán, G. E., Alvarado-Silva, C., Castañeda-Renderos, O. H., Vanoye-Carlo, E. G., la Torre, C. F.-D., Dueñas‐González, A., et al. (2020) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.20000060 · Cited by 7
PD-1/PDL1 Blockade Exacerbates Pancreatic Damage and Immune Response in a Mouse Model of Acute Pancreatitis
Xie, T., Wang, N., Yao, G., Xu, S., Wang, D., Liu, X., Hu, L., Lu, G., Shi, R., & Ding, Y. (2021) · Inflammation · doi:10.1007/s10753-021-01430-1 · Cited by 7
5mC-Related lncRNAs as Potential Prognostic Biomarkers in Colon Adenocarcinoma
Huang, Y., Huang, Y., Wang, Y., Liu, H., & Huang, Y. (2022) · Biology · doi:10.3390/biology11020231 · Cited by 7
Comprehensive Analysis of the Immune Implication of AKAP12 in Stomach Adenocarcinoma
Xu, Z., Xiang, L., Peng, L., Gu, H., & Wang, Y. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/3445230 · Cited by 7
The efficacy of PD ‐1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study
Sato, R., Kumai, T., Ishida, Y., Yuasa, R., Kubota, A., Wakisaka, R., Komatsuda, H., Yamaki, H., Wada, T., & Harabuchi, Y. (2022) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.863 · Cited by 7
Design, Synthesis, and Evaluation of 8-(o-Tolyl)quinazoline Derivatives as Small-Molecule PD-1/PD-L1 Antagonists
Wu, X., Li, H., Liu, H., Ding, X., Chen, X., Yin, C., Gao, Y., & Ma, J. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00014 · Cited by 6
Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance
Zhu, H., Yang, X., Zhao, Y., & Cheng, Y. (2019) · Medicine · doi:10.1097/md.0000000000015755 · Cited by 6
Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis
Zhou, Z.-Y., Liu, S.-R., Xu, L.-B., Liu, C., & Zhang, R. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00056 · Cited by 6
Predictive value of tumor-infiltrating lymphocytes detected by flow cytometry in colorectal cancer
Hu, Y., Zhao, J., Shen, Y., Zhang, C., Xia, Q., Zhang, G., Wang, B., Wei, B., Yu, R., Ma, J., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109286 · Cited by 6
Genomic and immunogenomic analysis of three prognostic signature genes in LUAD
Feng, H., Zhao, Y., Yan, W., & Li, B. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05137-y · Cited by 6
HUVECs affect HuT-78 cell apoptosis and cytokine production via the HIF-1α-PD-L1/PD-1 pathway under hypoxia
Qiang, L., Hong, L., Xu, J., & Zhanlin, Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110010 · Cited by 6
Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment
Carreira, B., Acúrcio, R. C., Matos, A. I., Peres, C., Pozzi, S., Vaskovich‐Koubi, D., Kleiner, R., Bento, M., Satchi‐Fainaro, R., & Florindo, H. F. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000147 · Cited by 6
The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis
Zhan, Z., Yao, W., Zhang, F., Qiu, W., Liao, K., Feng, J., Tan, J., Liu, H., Yuan, T.-Z., Zheng, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719650 · Cited by 6
T cell co-stimulator inducible co-stimulatory (ICOS) exerts potential anti-atherosclerotic roles through downregulation of vascular smooth muscle phagocytosis and proliferation
Zhong, Z., Zhang, Q., Tan, L., Guo, X., & Gan, C. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-7342 · Cited by 6
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
Zhang, Z., Xie, C., Gao, T., Yang, Y., Yang, Y., & Zhao, L. (2023) · BMC Cancer · doi:10.1186/s12885-023-10613-y · Cited by 6
Inter-Molecular Electrostatic Interactions Stabilizing the Structure of the PD-1/PD-L1 Axis: A Structural Evolutionary PerspectivePreprint
Li, W. (2020) · Preprints.org · doi:10.20944/preprints202001.0130.v1 · Cited by 5
A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors
Donati, G., Viviano, M., D’Amore, V. M., Cipriano, A., Diakogiannaki, I., Amato, J., Tomassi, S., Brancaccio, D., Russomanno, P., Leva, F. S. D., et al. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300583 · Cited by 5
Ethical Perspectives on Pharmacogenomic Profiling
Scionti, F., Pensabene, L., Martino, M. T. D., Arbitrio, M., & Tagliaferri, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00139-0 · Cited by 5
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
Freemantle, N., Xu, Y., Wilson, F. R., Guyot, P., Chen, C.-I., Keeping, S., Konidaris, G., Chan, K., Kuznik, A., Atsou, K., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221105024 · Cited by 5
Efficacy and toxicity of anlotinib plus camrelizumab versus anlotinib plus S-1 as second-line therapy for advanced esophageal squamous cell carcinoma: A real-world retrospective study
Zhang, W., Chen, M., Dai, H., & Sun, W. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.12.003 · Cited by 5
PD-1 agonist: A novel therapeutic approach to resolve atherosclerosis
Chen, J., Yu, W., Liao, L., Fu, L., & Yang, P. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101892 · Cited by 5
Cytokine Therapy in Bladder Cancer: Mechanisms, Efficacy, and Future Prospects
Oyler, H. J., Bruton, L. G., Maher, A. J., Yu, D., Shely, N. W., Wakefield, M. R., & Fang, Y. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040278 · Cited by 5
CD300a: An Innate Immune Checkpoint Shaping Tumor Immunity and Therapeutic Opportunity
Peng, J., & Liu, H. (2025) · Cancers · doi:10.3390/cancers17111786 · Cited by 5
Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions
Khan, M., Samaniego, F., Hagemeister, F. B., & Iyer, S. P. (2021) · Cancers · doi:10.3390/cancers13225627 · Cited by 5
[Relationship between ultrasound-findings of low-echoic nodule of hepatic parenchyma in liver cirrhosis and development of hepatocellular carcinoma].
Mikami, N., Ebara, M., Yoshikawa, M., & Ohto, M. (1990) · PubMed · Cited by 5
Enhancing T cell infiltration in glioblastoma: a review article on challenges and therapeutic strategies
Habibi, M. A., Nejati, N., Najafi, M. B., Khodadadiyan, A., Dashti, M., Lorestani, P., Karimizadeh, Z., Ahmadpour, M., Kalantari, A., Jokar-Derisi, A., et al. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100999 · Cited by 5
An EBNA1-YAP signaling axis drives immune escape through CD276 in EBV-associated gastric cancer
Huang, B., Liu, M., Duan, Y., Guo, J., Wang, Z., Dou, Y., Wang, M., Abuhaidar, O., Sun, H., Kee, L. S., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08251-2 · Cited by 4
Bromodomain and extra-terminal proteins in solid tumors: regulators of immune microenvironment and emerging therapeutic targets
Sharma, D., Bushnell, G. G., Kalman, A. P., Hutchens, C. M., & Burness, M. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1727365 · Cited by 4
Quantitative analysis of multiple breast cancer biomarkers using DNA-PAINT
Chen, Z., Yin, G., Wei, J., Qi, T., Qian, Z., Wang, Z., Zong, S., & Cui, Y. (2022) · Analytical Methods · doi:10.1039/d2ay00670g · Cited by 4
Fecal microbiota transplantation and its repercussions in patients with melanoma refractory to anti-PD-1 therapy: scope review
Barbosa, E. C., Bucar, E. E. C., JUBÉ, G. R., SILVEIRA, L. B., SILVA, N. C. D., FARIA, P. C. C., Ramos, P., Moraes, V. R. Y., & BARROS, J. O. B. (2023) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20233490-en · Cited by 5
Sumo-regulatory SENP2 controls the homeostatic squamous mitosis-differentiation checkpoint
Galán-Vidal, J., García-Gaipo, L., Molinuevo, R., Dias, S., Tsoi, L. C., Gómez‐Román, J., Elder, J. T., Hochegger, H., & Gandarillas, A. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06969-z · Cited by 4
Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes
Zhao, J., Guo, H., Wu, C., & Guo, H. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03707-x · Cited by 4
Nivolumab-DTPA-Based PD-1 Imaging Reveals Structural and Pathological Changes in Colorectal Carcinoma
Li, D., Li, X., Yang, J. M., Shi, Z., Zhang, L., Li, R., Ye, P., Liu, J., & Zuo, C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.839756 · Cited by 4
Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
Lu, S., Lou, Y., Rong, Y., Huang, Z., Lin, X., Chen, J., & Luo, K. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01295-2 · Cited by 4
Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis
Xiao, L., Kang, W., Liao, J., & Li, Y. (2021) · Brazilian Journal of Otorhinolaryngology · doi:10.1016/j.bjorl.2021.04.002 · Cited by 4
Surgery/non-surgery-based strategies for invasive locally-advanced non-small cell lung cancer in the era of precision medicine
Wang, M., Wang, B., Chen, X., Mei, T., Yang, X., Luo, Q., Na, F., & Gong, Y. (2024) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2024.116132 · Cited by 3
Photothermal-triggered non-apoptotic regulated cell death-related pathway regulation boosts systemic antitumor immunity
Liang, Y., Yuan, H., Jin, Q., Chen, A., Chen, W., Bai, Y., Wang, X., Ma, J., Hou, M., Wong, Y. K., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102479 · Cited by 3
Combination therapy strategies in engineered 177Lu radiopharmaceuticals beyond single modality: design principles and application outlet
Zhu, Y., Zhong, G., Zhang, W., Wei, W., Yin, B., & Zhang, K. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02700-x · Cited by 3
LPS combined with CD47mAb enhances the anti‑osteosarcoma ability of macrophages
Yuan, P., Que, Y., Liu, Y., He, P., Guo, Z., & Hu, Y. S. (2023) · Oncology Letters · doi:10.3892/ol.2023.13777 · Cited by 3
Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden
Sagredou, S., Dalezis, P., Papadopoulou, E., Voura, M., Deligiorgi, M. V., Nikolaou, M., Panayiotidis, M. I., Nasioulas, G., Sarli, V., & Trafalis, D. T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060885 · Cited by 3
An Immune-Gene-Based Classifier Predicts Prognosis in Patients With Cervical Squamous Cell Carcinoma
Yang, H., Han, X., & Hao, Z. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.679474 · Cited by 4
Alzheimer’s neuroinflammation: A crosstalk between immune checkpoint PD1-PDL1 and ApoE-Heparin interactions?
Patil, S. P., DiFlumeri, J., Wellington, J., Fattakhova, E., & Oravic, M. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110865 · Cited by 3
Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis
Ding, Y., Sun, C., Hu, L., Xiong, S., & Zhai, Z. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05325-z · Cited by 3
Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis
Yang, X., Zheng, X., Hu, S., Huang, J., Zhang, M., Huang, P. C., & Wang, J. (2024) · BMC Cancer · doi:10.1186/s12885-024-12423-2 · Cited by 3
Prognostic Role of OX40, LAG-3, TIM-3 and PD-L1 Expression in Bone and Soft Tissue Sarcomas
İnci, B. K., Acar, E., Gürler, F., İlhan, A., Yıldız, F., Ardıç, F., Öksüzoğlu, B. Ç., Özdemir, N., Özet, A., Esendağlı, G., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123620 · Cited by 3
Comprehensive Advanced Physicochemical Characterization and In Vitro Human Cell Culture Assessment of BMS-202: A Novel Inhibitor of Programmed Cell Death Ligand
Sofi, H. S., Lora, A. J., Donow, H. M., Dickinson, S. E., Wondrak, G. T., Chow, H. ‐. S., Curiel‐Lewandrowski, C. N., & Mansour, H. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111409 · Cited by 3
Adaptive immune response in pathogenesis and treatment of head and neck squamous cell carcinoma: the influence of immunosuppression factors and gender
Stukan, А. I., Murashko, R. A., Tsygan, N. A., Goryainova, А. Y., Nefedov, O. N., & Porkhanov, V. A. (2022) · Head and neck tumors (HNT) · doi:10.17650/2222-1468-2022-12-3-114-126 · Cited by 3
Safety and toxicity risks of radiotherapy combined with PD-1/PD-L1 inhibitors: A comprehensive review
Zeng, L., Yang, J. Y., Xia, H., Li, Z., Lin, Y. W., Yao, Q., & Zheng, R. (2025) · iScience · doi:10.1016/j.isci.2025.112882 · Cited by 2
Oxygen-carrying nanovaccine potentiates cancer immunotherapy for heterogeneous solid tumors
Tian, J., Yang, Z., Wan, S., Shou, C., Zhang, L., Zhao, Y., Chen, S., Huang, K., Zhao, H., Song, X., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102875 · Cited by 2
The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation
Yu, X., Li, T., Shen, Z., Jing, H., Xie, X., Zhou, X., Shen, Y., & Yang, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109704 · Cited by 2
Aerobic exercise prevents and improves cognitive dysfunction caused by morphine withdrawal via regulating endogenous opioid peptides in the brain
Dai, S., Dong, Y., Shi, H., Jin, J., Gan, Y., Li, X., Wu, Y., Wang, F., Hu, Q., Hu, Q., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06698-3 · Cited by 4
Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R
Markman, B., Kao, S. C.-H., Pavlakis, N., Bray, V., Packer, L., & Siva, S. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100929 · Cited by 2
PD-1 Inhibitors: Safety of Use and Management of Immune-Mediated Adverse Reactions in Patients With Head and Neck Cancer
Lewis, R. L., & Miller, K. (2019) · Clinical journal of oncology nursing · doi:10.1188/19.cjon.627-638 · Cited by 2
A Novel Classification and Scoring Method Based on Immune-Related Transcription Factor Regulation Patterns in Gastric Cancer
Wang, G., Huangfu, L., Gao, X.-Y., Gan, X., Xing, X., & Ji, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.887244 · Cited by 2
Immune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2
Immunotherapeutic Approaches in Cancer Treatment
Zhao, L., Zhong, L., Xu, S., & Li, B. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152061902190418105255 · Cited by 2
Detailed role of SR-A1 and SR-E3 in tumor biology, progression, and therapy
Saadh, M. J., Pallathadka, H., Abed, H. S., Menon, S. V., Sivaprasad, G. V., Hjazi, A. M., Rizaev, J. A., Suri, S., Jawad, M. A., & Husseen, B. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01350-5 · Cited by 1
Simple porphyrin nanoparticles for combined photo-immunotherapy of colorectal cancer
Sun, H., Fan, Z., Pei, Q., Xie, Z., Zhang, T., & Ma, C. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214466 · Cited by 1
Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo
Zhang, X., Zhang, L., Sun, Z., Xu, C., Tan, J., Ren, Y., Zhang, J., Chen, T., Wang, Z., Kong, D., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109477 · Cited by 1
Design, Synthesis and Biological Evaluation of Oxadiazole-Biphenyl Derivatives as Small Molecule Inhibitors Targeting PD-1/PD-L1 Immune Checkpoint
Xie, L., Zhu, M., Zhao, T., Pei, Y., Wei, B., Zhu, S., Chen, J., Zhang, H., & Zhou, J. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00048 · Cited by 1
Vibration properties of immune‐oncological drugs
Tavares, A. B. M. L. A., & Albuquerque, E. L. (2022) · Journal of Raman Spectroscopy · doi:10.1002/jrs.6297 · Cited by 1
Immune Checkpoint Inhibitors Programmed Cell Death-1/Programmed Cell Death-Ligand1 (PD-1/PD-L1) for Cancer Therapy
Bebars, S. M. M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.108366 · Cited by 1
Transplante de microbiota fecal e suas repercussões em pacientes com melanoma refratário à terapia anti-PD-1: revisão de escopo
Barbosa, E. C., Bucar, E. E. C., JUBÉ, G. R., SILVEIRA, L. B., SILVA, N. C. D., FARIA, P. C. C., Ramos, P., Moraes, V. R. Y., & BARROS, J. O. B. (2023) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20233490 · Cited by 1
Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study
Yu, Y., Wu, T., Gan, W., Liu, C., Zhang, R., Zheng, J., Xiong, J., Chen, J., & Li, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03453-0 · Cited by 1
Progress of Oncolytic Virus
Wu, C., Zhao, Y., Hu, K., & Zhong, L. (2024) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2024.3917 · Cited by 1
Checkpoint blockade therapy in Hodgkin lymphoma: improved response through combination with JAK inhibition
Weniger, M. A., & Küppers, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01968-0 · Cited by 1
Sleep apnoea and immune regulation: The story is only beginning
Lam, D. C.-L., & Ip, M. (2019) · Respirology · doi:10.1111/resp.13565 · Cited by 1
Leishmania donovani
Habib, S., Azab, M. S., Elmasry, K., & Handoussa, A. E. (2021) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.315895 · Cited by 1
An Antiangiogenic Agent Associated with Multi-Targets Exhibits Synergistic Antitumor Effects in Combination with Immunotherapeutics
Xue, L. (2022) · Journal of Oncology Research and Therapy · doi:10.29011/2574-710x.10123 · Cited by 1
Immunoimaging
Shaikh, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-9535-3_17 · Cited by 1
Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma
Fixsen, E. (2022) · Cutis · doi:10.12788/cutis.0637 · Cited by 1
A cost-effectiveness analysis of toripalimab plus TP versus TP for the first-line treatment of advanced esophageal cancerPreprint
Zeng, F., Ye, Z.-M., Wang, H.-L., Xu, Z., Zhou, Q., & Li, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1702257/v1 · Cited by 1
Commentary: CD22 blockade restores homeostatic microglial phagocytosis in ageing brains
Wei, P., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01301
Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients
Yamaguchi, K., Ninomiya, S., Matsumoto, T., Nakamura, N., Nakamura, H., Kitagawa, J., Kanemura, N., Hara, T., Fujigaki, S., Yamamoto, Y., et al. (2020) · Hemato · doi:10.3390/hemato1020011
Antibiotics Treatment and Immune-checkpoint Inhibitors Efficacy: A Systematic Review and Meta-analysisPreprint
Hao, J., Zhao, Y., He, J., Wang, Y., & Dong, Y. (2020) · doi:10.21203/rs.3.rs-30778/v1
Berberine enhances the anti-HCC effect of NK cells through inhibiting interferon-gamma-mediated PD-L1 expressionPreprint
Wang, K., Gu, C., Yu, G., Lin, J., Wang, Z., Lu, Q., Xu, Y., Zhao, D., Jiang, X., Zhou, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-353093/v1
Complete Response Associated With Combination Treatment Regorafenib and Sintilimab in a Sorafenib-refractory Hepatocellular Carcinoma PatientPreprint
Zhang, E., Zhang, Z., Zhang, L., Xiang, S., Chen, X., & Zhiyong, H. (2020) · Research Square · doi:10.21203/rs.3.rs-49286/v1
Role of checkpoint inhibitors immunotherapy in non-muscle invasive bladder cancer: current methods and future perspectives
Agag, A. A., Naushad, N., Manzoor, A., Abbas, S. A., Deb, A. A., & Serag, H. A. (2021) · Urology & Nephrology Open Access Journal · doi:10.15406/unoaj.2021.09.00313
Maprotiline Prompt the Anti-tumor Effect by Inhibiting the PD-L1 in Mice Burdened MelanomaPreprint
Zhao, T., Li, Y., Liu, M., Zhou, L., Wu, Z., Chen, H., Guo, J., Gao, M., Zhong, J., Wang, M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1172486/v1
Atovaquone-HSA Nano-drugs Enhance the Efficacy of PD-1 Blockade Immunotherapy by Improving Hypoxic Tumor MicroenvironmentPreprint
Wang, S., Zhou, X., Zeng, Z., Sui, M., Chen, L., Feng, C., Huang, C. Y., Yang, Q., Ji, M., & Hou, P. (2021) · Research Square · doi:10.21203/rs.3.rs-502600/v1
A Novel Gene Expression Signature-Based on B-Cell Proportion to Predict Prognosis of Patients with Lung AdenocarcinomaPreprint
Zhang, Y., Xuewen, Y., Wang, Q., Song, X., Wenjie, X., Mao, Q., Chen, B., Liang, Y., Zhang, T., Xu, L., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-585268/v1
Anti-PD-L1 Antibody Alleviate Pulmonary Fibrosis by Inducing Autophagy via Inhibition of the PI3K/Akt/mTOR PathwayPreprint
Lu, Y., Zhong, W., Liu, Y., Chen, W., Zhang, J., Zeng, Z., Huang, H., Qiao, Y., Wan, X., Meng, X., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3947644
A Systematic Pan-Cancer Analysis of SPATS2L, a Potential New Immunological and Prognostic BiomarkerPreprint
Cao, Y., Yang, Y., Li, Q., Wang, X., Lu, H., Guo, Z., Yao, C., Xiao, L., & Xie, L. (2023) · Research Square · doi:10.21203/rs.3.rs-2494003/v1
Immunotherapy for Sarcoma
Pilavaki, P., & Constantinidou, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_235-1
Expression of PD-L1 in malignant soft tissue neoplasm and their correlation with clinicopathological parameters
Mishra, A., Singh, A. K., Kumar, M. S., Sagar, M., Kumari, M., Qayoom, S., & Kumar, V. (2023) · Journal of Laboratory Physicians · doi:10.1055/s-0043-1771241
A Systematic Pan-Cancer Analysis and Experimental Verification Reveals SPATS2L as a Potential New Immunological and Prognostic Biomarker of Lung adenocarcinomaPreprint
Yang, Y., Cao, Y., Zhang, H., Li, Q., Wang, X., Lu, H., Yao, C., & Xie, L. (2023) · Research Square · doi:10.21203/rs.3.rs-3648599/v1

Authors: Constantinidou, A., Alifieris, C., & Trafalis, D. T.
Affiliations: University of Cyprus (CY)
National and Kapodistrian University of Athens (GR)
Corresponding author: Trafalis, Dimitrios T.
ORCID: Constantinidou, Anastasia
Alifieris, Constantinos
Trafalis, Dimitrios T.
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2019-02
Volume: 194
Pages: 84-106
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2018.09.008
OpenAlex: W2894101188
Cited by: 342
References: 230
Citations by year: 2026: 13 · 2025: 16 · 2024: 43 · 2023: 51 · 2022: 58 · 2021: 72 · 2020: 53 · 2019: 35
FWCI: 4.31
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: PD-1 inhibitors, PD-L1 inhibitors, immune checkpoint blockade, cancer immunotherapy, melanoma, renal cell carcinoma, lung cancer, Hodgkin's disease, urothelial carcinoma, head and neck cancer, combination therapy, toxicity profile, predictive biomarkers, regulatory approval
MeSH terms: Antineoplastic Agents, Immunological, Animals, Humans, Immunotherapy, Neoplasms, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks